Holzkirchen, February 10, 2016 – Today, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG).I…
Holzkirchen, February 10, 2016 – Today, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG).I…
Basel, January 27, 2016 – Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operationsStrong growth (cc) in full year sales, core operating income and core …
Basel, January 27, 2016 – Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operationsStrong growth (cc) in full year sales, core operating income and core …
Holzkirchen, 25 January, 2016 – Sandoz, a Novartis company and the global leader in biosimilars, announced today that it has entered into an exclusive license agreement with Kyowa Hakko Kirin Co., Ltd for the distribution and promotion of its biosimila…
Rex Clements, Head of Business Unit Anti-Infectives & API comments on the antimicrobial resistance declaration:Listen to the audio (1:23 min).mp3 …
Sandoz is seeking approval for all indications included in the reference product’s label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis.Sandoz believes that the totality of evidence in its submission, including t…
PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer.The study met its primary endpoints demonstrating equivalence and non-infe…
The Novartis Group of companies, recently provided comments on the U.S. Food and Drug Administration (FDA) Proposed Rule entitled “Designation of Official Names and Proper Names for Certain Biological Products”.As the first company to market a biosimil…
Sandoz demonstrates commitment to oncology by seeking approval for its proposed biosimilar pegfilgrastim.Sandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, will demonstrate that the proposed biosi…